ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,755 | +66.2% | 500,000 | 0.0% | 0.12% | -13.4% |
| Q1 2023 | $2,260 | -59.9% | 500,000 | 0.0% | 0.13% | -57.5% |
| Q4 2022 | $5,635 | -99.9% | 500,000 | 0.0% | 0.32% | +54.4% |
| Q3 2022 | $4,785,000 | +18.3% | 500,000 | 0.0% | 0.20% | -5.6% |
| Q2 2022 | $4,045,000 | -52.1% | 500,000 | 0.0% | 0.22% | -39.0% |
| Q1 2022 | $8,450,000 | -21.4% | 500,000 | 0.0% | 0.35% | +21.2% |
| Q4 2021 | $10,745,000 | -70.9% | 500,000 | 0.0% | 0.29% | -64.6% |
| Q3 2021 | $36,930,000 | +35.1% | 500,000 | 0.0% | 0.83% | +48.8% |
| Q2 2021 | $27,340,000 | -29.4% | 500,000 | -4.8% | 0.56% | -18.9% |
| Q1 2021 | $38,714,000 | +49.7% | 525,000 | +75.0% | 0.68% | +23.2% |
| Q4 2020 | $25,860,000 | +585.2% | 300,000 | +200.0% | 0.56% | +503.3% |
| Q3 2020 | $3,774,000 | – | 100,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |